Sildenafil plus Low Dose Aspirin for Prevention of Preeclampsia: A Randomized Controlled Trial
Abstract
Objective: To compare
between the efficacy of the use of oral sildenafil plus low dose aspirin versus
the use of oral low dose aspirin alone in pregnancy as preventive measure in women
at risk for preeclampsia (PE). Design: A randomized clinical trial. Setting: Outpatient Obstetric clinic of Ain Shams University Maternity Hospital. Population
or sample: Women at gestational age of ≤16 weeks who at risk for PE between June 2018 and June 2019. Methods: Participants were randomly allocated into two groups: Group I Included 200 women
who received a 25 mg tablet of oral sildenafil citrate tid until delivery plus 100
mg tablet of aspirin orally once daily until gestational age of 36 weeks, Group
II Included 200 women who received a 100 mg tablet of aspirin orally once daily
until gestational age of 36 weeks. Main Outcome Measures: Incidence of preeclampsia
diagnosed per ACOG criteria. Results: The incidence of PE in both groups
showed no statistically significant difference. The incidence of PE in the first
group is 11.0%, and it is 12.0% in the second group (p-value 0.754). Conclusion: The addition of sildenafil citrate to low dose aspirin had no impact on the prevention
of preeclampsia for women at risk of PE, in addition, sildenafil did not improve
maternal and fetal outcomes.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.